Novavax rose 11.3% during the aftermarket session to $12.26 per share. As reported by Reuters: "Jan 9 ( Reuters ) - Novavax Inc ( NVAX.O ) said on Monday its longtime chief executive officer, Stanley Erck, would retire and be succeeded by industry veteran John Jacobs, at a time when the COVID-19 vaccine maker looks to catch up with larger rivals. Novavax shares were up about 5% in ..." You can read more about it here. For those of you thinking about investing in the stock, here is a brief look at the company's fundamentals.
Here's an overview of Novavax's recent cash flows and operating margins:
|Date Reported||Cash Flow from Operations ($ MM)||Capital expenditures ($ MM)||Free Cash Flow ($ MM)||YoY Growth (%)|
|Date Reported||Total Revenue ($ MM)||Operating Expenses ($ MM)||Operating Margins (%)||YoY Growth (%)|
At today's price of $12.26 per share, Novavax is -77.84% away from its target price of $55.33, and on average, analysts give the stock a rating of hold. 31.3% of the company's shares are linked to short positions, and 43.6% of the shares are owned by institutional investors.